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Abstract
Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade
therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival
in a variety of cancers. However, many patients do not benefit, possibly due to insufficient spontaneous T cell reactivity
against their tumors and/or lacking immune cell infiltration to tumor site. Such tumor-specific T cell responses could be
induced through anti-cancer vaccination; but despite great success in animal models, only a few of many cancer
vaccine trials have demonstrated robust clinical benefit. One reason for this difference may be the use of potent,
effective vaccine adjuvants in animal models, vs. the use of safe, but very weak, vaccine adjuvants in clinical trials.
As vaccine adjuvants dictate the type and magnitude of the T cell response after vaccination, it is critical to understand
how they work to design safe, but also effective, cancer vaccines for clinical use. Here we discuss current insights into
the mechanism of action and practical application of vaccine adjuvants, with a focus on peptide-based cancer vaccines.
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CFA, Complete Freund’s adjuvant; cGAS, Cyclic GMP-AMP synthase; CTL, Cytotoxic T lymphocytes; CTLA-4, Cytotoxic
T-lymphocyte-associated protein 4; DAMP, Damage associated molecular patterns; GM-CSF, Granulocyte macrophage
colony- stimulating factor; HBV, Hepatitis C virus; HPV, Human papilloma virus; IFA, Incomplete Freund’s adjuvant;
IFN, Interferons; IL, Interleukin; IRF, Interferon response factors; MPL, Monophospholipid A; NK, Natural killer cells;
Mɸ, Macrophage; PAMP, Pathogen associated molecular patterns; PD-1, Programmed cell death protein 1;
pDC, Plasmacytoid dendritic cells; PLA, Poly(lactic acid); PLG, Poly(lactide-co-glycolide); PLGA, Poly(lactic-co-glycolic
acid); poly IC, Polyinosine-polycytidylic acid; PPR, Pattern recognition receptors; RLR, C-type lectin receptors and retinoic
acid inducible gene (RIG)-I-like receptors; STING, Stimulator of interferon genes; Th (1,2,17), Helper T cells (type 1, 2, 17);
TLR, Toll-like receptors; TNF, Tumor necrosis factors; Treg, Regulatory T cells; TRIF, TIR-domain-containing adapter-
inducing interferon-β; VdLN, Vaccination site-draining lymph node
Background
The goal of a therapeutic cancer vaccine is to induce the
activation and proliferation of T cells, in particular cyto-
toxic T lymphocytes (CTL), which specifically recognize
and kill cancer cells leading to improved therapeutic
outcome for the patient. To maximize CTL responses,
an ideal vaccine adjuvant must fulfill two major func-
tions. First, it must provide optimal availability of the
antigen (Ag, signal 1) by regulating its persistence, loca-
tion, concentration and presentation by antigen presenting
cells (APC). Second, it must enhance the immune res-
ponse by inducing the expression of co-stimulatory
molecules (signal 2) and cytokines (signal 3) by APC [1].
Suboptimal delivery of any of these signals can result in
poor T cell numbers and/or function.
Antigen delivery systems
Antigen delivery systems facilitate signal 1 by different
mechanisms. First, they extend Ag presentation time by
protecting Ag from degradation by cell-associated serum
proteases and peptidases [2]. Second, they enhance the
uptake of tiny antigenic peptides by APC by forming
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them into particles of a size similar to that of pathogens
(micrometer or submicrometer size) [3]. Third, some
delivery systems can promote the localization of Ag to
peripheral draining lymph nodes which increases the
chance of encountering draining lymph node-resident
APC, resulting in increased Ag-presentation to T cells [4].
Collectively, these mechanisms enhance T cells response
number by extending Ag presentation time to be optimal
for T cell clonal expansion, effector function and/or mem-
ory formation [5, 6] (Fig. 1). Mode of action, the types of
responses, and advantage/disadvantages of selected anti-
gen delivery systems are shown in Table 1. Of notice,
vaccination can also allow for the delivery of immunodo-
minant or neoantigen epitopes, resulting in enhanced
anti-tumor efficacy.
Besides signal 1, antigen delivery systems can also de-
liver signal 2 and 3 by activating the innate immune cells.
Aluminum, PLG and polystyrene particles were shown to
activate the inflammasome complex in a phagocytosis-
dependent manner while carbon nanotubes trigger the
complement system (see below). Adjuvants vary in the
quality and quantity of signals 1, 2 and 3 they deliver to
T cells. These attributes of adjuvants become especially
important when using them to vaccinate with antigens
that possess very little, if any, inherent adjuvant activity,
such as the minimally defined peptide epitopes typically
used in peptide vaccines. Here we discuss some adjuvants
that are commonly used in peptide-based cancer vaccines.
Incomplete Freund’s adjuvant (IFA)
IFA is a water-in-oil emulsion, identical to Complete
Freund’s Adjuvant (CFA) but without the heat-killed
Mycobacteria tuberculosis to avoid acute granulomatous
lesions at vaccine sites. It has previously been shown
that IFA promotes long-term retention and slow release
of emulsified antigen at the inoculation site [7, 8]. Likely
as a result of this, IFA induces strong humoral and cellu-
lar immune responses. Clinical-grade IFA (Montanide™
oil series, SEPPIC Corp.) has been widely used clinically
in experimental peptide and protein-based cancer vac-
cines [9]. Recently, our group showed that IFA-based
peptide vaccines can induce potent cytotoxic CD8 T cell
responses in mice, followed by T cell retention, exhaustion
and deletion at the vaccination site, due to excessively
long-term peptide Ag retention and chronic release by the
poorly biodegradable IFA emulsion [10]. Mechanistically,
the long-term antigen presentation and consequent T cell
recognition and cytokine release at the vaccination site
induced chronic tissue inflammation and chemokine pro-
duction that attracted and retained effector T cells, pre-
venting them from reaching the tumor site. Eventually,
persistent antigen stimulation at the vaccination site re-
sulted in T cell exhaustion and Fas/FasL-mediated T cell
apoptosis. Of notice, this observation was obtained using
vaccines based on minimal epitope-sized short peptides
which can be presented by any MHC Class I-positive,
nonprofessional APC [11]. In contrast, longer peptides
Fig. 1 Mechanisms of action of vaccine adjuvant. Left, some adjuvants can function as antigen delivery systems to affect the geographical availability of
the antigen (signal 1). Right, adjuvants also commonly stimulate antigen presenting cells (APC) and induce them to upregulate co-stimulatory molecules
such as CD80/CD86 (signal 2) and/or produce cytokines such as IL-12 (signal 3). VdLN: vaccination site-draining lymph node
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require trimming by DC-specific enzymes to allow effi-
cient binding to MHC Class I molecules, and hence they
are presented exclusively by the relatively small population
of DC in the context of optimal co-stimulatory molecules
and cytokines for efficient T cell priming [12]. Indeed, long
peptides emulsified in IFA induced minimal T cell traf-
ficking to vaccine sites and greatly reduced contraction
of T cell levels [10]. It is also proposed that long pep-
tides which contain helper T cell epitopes will induce
Th response to further enhance the CTL response [12].
However, in 2 separate clinical trials using IFA, separate
Th epitopes mixed with short CTL epitopes failed to
improve CTL response in patients with metastatic mel-
anoma [13, 14]. This might be due to a difference in
the nature of the antigens: virus-derived long peptides
containing both Th and CTL epitopes vs. melanocyte
self antigen-derived short CTL epitope peptides mixed
with short Th epitope peptides. Given the clear benefit
of CD4+ T cell responses in the generation and intratu-
moral function of CD8+ T cells [15, 16], further studies
are needed to reconcile this discrepancy. Nevertheless,
our preclinical data suggest that prolonged Ag presen-
tation (signal 1), even in the presence of signal 2 and 3,
can induce T cell retention, exhaustion and deletion.
Aluminum adjuvants
Generally referred to as alum, both aluminum hydroxide
(Alhydrogel™) and aluminum phosphate (Adjut-phos™)
adjuvants are widely used in human vaccines such as
those against influenza, tetanus, diphtheria, pertussis,
poliomyelitis, and HPV [17]. During vaccine preparation,
antigens are adsorbed to preformed aluminum adju-
vants, hence their name aluminum-adsorbed vaccines.
Aluminum adjuvants are known to promote Th2 re-
sponses which make them less suitable for vaccines
against intracellular bacteria such as M. tuberculosis,
which require a Th1-type immune response dominated
by IFN-γ [18]. When combined with MPL (a detoxified
form of lipopolysaccharide, LPS), a TLR4 agonist, such
as in the AS04 adjuvant system (Glaxo SmithKline),
alum-based vaccines induce Th1 responses with produc-
tion of IFN-γ and IgG2a. In 2008, alum adjuvants were
found to activate the NALP3 inflammasome in DC [19].
Inflammasome activation leads to the production of pro-
inflammatory cytokines including IL-1β and IL-18 which
promote the adaptive cellular (Th1/Th17/Th2) and
humoral responses [20]. IL-1β promotes Th1 and Th17
while IL-18 serves as coactivator for other cytokines. In
the presence of IL-12 and IL-15, IL-18 contributes to
Th1 response via promoting IFN-γ production. In the
absence of IL-12, IL-18 induces IL-4 which drives Th2
response [21]. Thus, adjuvants that activate the inflam-
masome, including alum, can induce different types of T
cell response, depending on tissue- or adjuvant-driven
cytokine context.
Micro/nano particles
Micro- and nano-particles are attractive antigen/drug de-
livery systems because they can combine several desired
characteristics. First, the particles protect their cargo from
serum/tissue peptidases/proteases and other degrading fac-
tors, thus increasing the half-life of encapsulated Ag and
immunomodulators in vivo. Second, particles can be engi-
neered to target specific cell types or organs (such as
lymph node) [22, 23]. These features help reduce both the
drug dose and off-target side effect. For example, it has
been shown that Ag encapsulated in poly(lactic-co-glycolic
acid) (PLGA) particles induce similar T cell response with
a 1000-fold lower dose compared to free Ag [24].
There are two basic ways to engineer particles for en-
hanced uptake by APC. Passive targeting relies on the
size, charge and rigidity of the particle while active tar-
geting is based on added ligands on the particle surface.
Vaccine particles with size range from 500 to 2000 nm
Table l Examples of class I adjuvants (delivery systems)




Depot Ab, Th1, Th2 Widely used for vaccines
when antibody production is
desired [123].
May not suitable for
therapeutic vaccine when
cellular response is desired as
extended depot will attract
CTL to vaccine sites [10].
Aluminum Depot, inflammasome activation Ab, Th2 Safety characters are well
defined as it is the most
widely used adjuvant [124].
Needs to be combined with






particlenature: increase Ag half-
life (via encapsulation, sustained
release) delivery Ag to target
cells/organs, cellular and
Inflammation induction (see text
for detail)
Not well defined but size of articles
may contribute to types of
response: size of 40–50 nm induces
stronger T cell response than 20nm
or 2000 nm particles 4.
Reduce Ag dose, cellular and
biological characters are well
defined, versatile to be
combined with other
adjuvants [121].
Rapid clearance in blood and
accumulation in filtering
organs such as liver and spleen
[24].
Need to be combined with
immunopotentiators.
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are preferentially trapped by tissue APC at the injection
site (which may then traffic to LN), while 20 to 200 nm
particles drain passively to LN where they are taken up
by resident APC. Beside their role as Ag/drug carrier, in-
creasing signal 1, micro and nanoparticles can also en-
hances signals 2 and 3. PLG and polystyrene particles
are thought to participate in inflammasome activation by
enhancing the IL-1β secretion by DC in a phagocytosis-
dependent manner [25]. Carbon nanotube particles, on
the other hand, activate the complement system and sub-
sequent inflammatory responses via binding to C1q [26].
Materials used to make micro and nanoparticles include
liposomes, synthetic polymers such as polystyrene,
poly(lactide-co-glycolide) PLG, poly(lactic acid) PLA,
PLGA or natural polymers such as gelatin, collagen
and chitosan. The choice of material depends on the
desired biocompatibility, half-life, hydrophobicity and po-
larity. For example, liposome particles are very versatile,
allowing combination of Ag and cytokines like IL-2 or
GM-CSF, into a single particle to provide better immune
response and protection [27]. However, major drawbacks
are the rapid clearing from the blood and accumulation in
the liver. Coating a liposome with polyethylene glycol
(PEG) or other biocompatible polymers can reduce rapid
systemic clearing and thus extend its half-life in vivo [28].
To improve the accumulation of a liposome to tar-
geted tissue or organ, its surface can be decorated
with receptors (e.g. antibodies) for target cell/tissue
ligands and such modified liposomes are called immuno-
liposomes. Micro- and nanoparticles such as hydro-
philic poly(DL-lactide-co-glycolide) microspheres and
poly(propylene sulfide) nanoparticles have been de-
signed to target the DC in draining LN [22, 23]. A
different approach is to attract DC to the site of vaccine
injection. Recent reports showed that incorporating GM-
CSF, CpG and tumor antigens in PLG matrices efficiently
attracted and stimulated both conventional DC (CD11c +
CD11b + and CD11c + CD8a+) and plasmacytoid DC,
resulting in superior immune responses (Th1 and CTL)
against B16 melanomas in mice [29, 30]. A very high con-
centration of GM-CSF (3000 ng) prolonged the DC reten-
tion in situ, resulting in suboptimal DC trafficking to
draining LN and the subsequent inferior T cell priming
and protection against tumor. This observation suggests
that delivery systems that stimulate the attraction of DC
can promote T cell responses, but only if they do not pre-
vent the DC from ultimately reaching the LN where T cell
priming typically occurs.
The antigen depot: what duration of antigen presentation
is optimal?
Our preclinical work with IFA as a vaccine adjuvant sug-
gests that prolonged antigen presentation has multiple
detrimental effects on the effector function, tumor
localization, and survival of vaccination-induced, tumor-
specific T cells [10]. However, extremely short antigen
presentation (such as after injection of minimal epitope
peptides in saline), especially in the absence of adjuvants
to induce signals 2 and 3, can likewise lead to subopti-
mal or even abortive/tolerogenic T cell activation. We
speculate that in successful, natural immune responses,
such as those against acute viral infections that are rap-
idly and completely cleared, the bulk of specific antigen
persists for a moderate duration, in the order of a few
days [31]. While there is clear evidence that small amounts
of antigens can be retained much longer in APC, the initial
large wave of antigen that primes the acutewave of T cell
effectors that follows within days of acute pathogen expos-
ure is typically gone within a week. By analogy, cancer vac-
cines with similar kinetics of antigen availability have the
best chance of priming a massive wave of tumor-specific
CTL. Indeed, we have observed such a bell-shaped curve
for T cell response and function after different duration of
antigen presentation in vivo (Khong et al., manuscript in
preparation). It will be interesting to see whether this is a
common principle, and whether this can be harnessed to
increase the potency and efficacy of peptide-based cancer
vaccines.
The immunopotentiators
When vaccinologists moved from whole pathogen vac-
cines (live, attenuated or dead pathogens) to recombinant
subunit vaccines for reasons of safety and manufacturing,
they learned that these vaccines typically evoked weaker
immunity and protection. The discovery of how our body
senses pathogens via a family of highly conserved pattern
recognition receptors (PRR) called Toll-like receptors
(TLR) [32–34] heralded the era of the specific receptor-
mediated activation of innate immunity. Since then, other
innate immune receptors have been discovered including
NOD-like receptors (NLR), C-type lectin receptors and
retinoic acid inducible gene (RIG)-I-like receptors (RLR)
and most recently cyclic GMP-AMP synthase (cGAS).
Within the last decades, numerous adjuvants have been
developed to target these innate receptors. Signaling
mechanisms of these receptors have been thoroughly
discussed elsewhere [35–38]; here we focus on the ad-
juvants that target these receptors, in particular those
that have entered clinical trials of cancer vaccines.
Some notable examples of immunopotentiators and
their stages of development are listed in Table 2.
Adjuvants targeting toll-like receptors
TLR2 agonists
TLR2 is expressed on the surface of different immune
cells like DC, macrophages and lymphocytes and recog-
nizes bacterial lipopeptides. Upon engaging its ligands,
TLR2 activates NF-kB via the MYD88 signaling pathway.
Khong and Overwijk Journal for ImmunoTherapy of Cancer  (2016) 4:56 Page 4 of 11
There are two common strategies to engage TLR-2
through vaccines: conjugating the antigen to bacterial
lipopeptides or to palmitic acid. Bacterial lipopeptide
MALP-2 and its synthetic analogues like Pam2Cys and
Pam3Cys are most frequently used. The peptide-
lipopeptide construct were shown to induce DC mat-
uration, pro-inflammatory cytokine (IL-12, TNF-α,
IFN-γ) secretion, B cell activation and enhanced CTL
responses [39]. Most current clinical trials of TLR-2
based adjuvants are for vaccination against infectious
diseases such as HIV, HBV and Lyme disease. In 2014,
vaccine using TLR-2 ligand (Pam3CSK4) conjugated
with long synthetic peptide showed very promising results
in a preclinical melanoma model [40]. Interestingly,
Pam3CSK4-peptide conjugate, but not the mixture of
Pam3CSK4 with peptide, induced robust T cell response
and protection against tumor. This is in line with the cis-
activation model showed by Desch et al. [41], which essen-
tially posits that signal 1 and 2 should be delivered by
same APC for optimal T cell priming.
TLR3 agonists
TLR3 is expressed in the endosomal compartment of con-
ventional dendritic cells (cDC), macrophages and on the
surface membrane of non-immune cells like epithelial
cells [42]. TLR3 is activated by double-stranded RNA or
its synthetic analog polyinosine-polycytidylic acid (poly
I:C) [43]. TLR3 does not use the MyD88 signaling path-
way but triggers TRIF signaling leading to activation of
NF-kB, MAP kinases and IRF3, which in turn induce the
production of inflammatory cytokines, type 1 interferons
(IFNs) and the subsequent upregulation of costimulatory
molecules [44].
Poly I:C can enhance antigen cross-presentation by
DC to CD8 T cells. Because of its rapid degradation by
serum nucleases in primates, poly I:C has limited anti-
tumor efficacy in humans [39]. Therefore, more stable
derivatives of poly I:C were made, including poly ICLC
(known as Hiltonol) and poly I:C12U [45]. In a phase 1
ovarian cancer trial, addition of poly ICLC to a vaccine
consisting of NY-ESO1 long overlapping peptides in IFA
dramatically induced rapid and efficient CD4 and CD8 T
cell responses, compared to the vaccine alone [46]. A re-
cent study in monkeys showed that poly ICLC in com-
bination with agonistic CD40 antibody significantly
enhanced both CD4 and CD8 responses compared to
either adjuvant alone [47]. This is some of the first pri-
mate data confirming the multitude of mouse studies
that indicated strong synergy when different classes of
immunopotentiators are used together in vaccine adjuvants
[10, 48, 49]. I:C12U and poly ICLC have entered clinical
trials for other cancer including glioma, melanoma, carcin-
oma (poly ICLC) and HER-2 positive breast cancer [39].
TLR4 agonists
TLR4 is expressed on the surface of immune cells in-
cluding cDC and macrophages as well as non-immune
cells such as fibroblasts and epithelial cells. Triggering
TLR4 will activate both MyD88 and TRIF dependent
pathways leading to NF-kB and IRF3/7 activation. TLR4
activation strongly promotes Th1 response through IL-
12p70 induction [50]. Due to its high toxicity, LPS has
Table 2 Examples of class 2 adjuvants (immunopotentiators)
Receptor Target cells Stage of development (not comprehensive) in cancer vaccine
“stepping on the gas”
Pam3CSK4 TLR2 DC, M$, lymphocytes Preclinical
Poly-ICLC TLR3 cDC, M$, epithelial cells Several clinical trials for different cancers.
MPLA TLR4 cDC, M$, epithelial cells,
fibroblasts
Clinical trial phase 2
Imiquimod TLR7/8 pDC, B cells, M$,
monocytes
Clinically approved for treating basal cell carcinoma. Multiple clinical trials in combination with
vaccine for different cancers.
CpG TLR9 pDc, B cells Multiple clinical trials
IL-2 IL-2Ra/
p/y
T, B and NK cells Clinically approved for treating renal carcinoma and melanoma. Multiple clinical trials in
combination with vaccine for different cancers.
GM-CSF GM-
CSFR
many Multiple clinical trials in combination with vaccine and checkpoint blockades for different cancers.
IFNs IFNR many Multiple clinical trials
CDNs STING many Preclinical
“releasing the brake”
a-PD1 Ab PD-1 T, B and NK cells Clinically approved for different cancers.
a-CTLA4 Ab CTLA-4 T cells Clinically approved for melanoma, under multiple clinical trials for different cancers.
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been replaced by the less toxic derivative, monopho-
sphoryl lipid A (MPLA), as vaccine adjuvant. The adju-
vanticity of MPLA has been studied extensively in
several clinical trials [39]. MPLA is used in combination
with aluminum (AS04) to skew the typical Th2 response
induced by alum to a Th1 response [51]. MPL as a vac-
cine adjuvant, in combination with tumor antigens, has
entered into several clinical trials for melanoma, lung,
and prostate cancer [52–54].
TLR7/8 agonists
Localizing within the endosomal compartments, both
TLR7 and 8 can recognize single stranded (ss) RNA as
they are structurally related [42]. In human, TLR7 is pre-
dominately expressed in plasmacytoid dendritic cells
(pDC) and to a lesser extent in B cells and monocytes/
macrophages while TLR8 is mainly expressed in mono-
cytes/macrophages and cDC [55]. TLR7/8 signal through
the MyD88 pathway leading to upregulation of co-
stimulatory molecules (CD80/86, CD40), production of
cytokines (IFN-α, TNF-α, IL-12) and migration of DC
from skin to lymph nodes. TLR8 is expressed, while
TLR7 is not, on the important BDCA3+ cDC subset that
is most potently responsible for cross-priming of CD8+
T cells [56], and thus preferential TLR7 agonists may
exert weaker adjuvant activity than TLR8 or TLR7/8 ag-
onists when used in CD8+ T cell-inducing vaccines.
TLR7/8 can also activate B cells to produce antibody
and cytokines such as IL-6 and TNF-α, and T cells to
proliferate and produce cytokines including IFN-γ and
IL-2 [57, 58]. TLR7/8 can be activated by synthetic imi-
dazoquinolines including imiquimod (mostly acts on
TLR7) and resiquimod (TLR7 and 8). Imiquimod
(Aldara cream) has been approved to treat basal cell car-
cinoma and genital warts [59, 60]. Several clinical trials
of imiquimod as vaccine adjuvant in different cancers in-
cluding chronic myeloid leukemia (CML), vulval intrae-
pithelial neoplasia (VIN), prostate cancer and melanoma
have been conducted [61–64]. Overall, all vaccines in-
duced both humoral and cellular responses in a major
fraction of patients. In vaccinated patients with VIN,
infiltration of both CD4 and CD8 T cells into tumor
sites was shown to correlate with tumor clearance [62].
TLR9 agonists
TLR9 is expressed by human B cells and pDC and localizes
in endo-lysosomal compartment [42]. Its role is to detect
unmethylated CpG motifs which are often found in bacter-
ial, but not host cell DNA. Upon activation, TLR9 induces
production of pro-inflammatory and Th1 cytokines (such
as IL-12) by APC. There are 3 classes of synthetic CpG oli-
gonucleotides (ODN) being used in preclinical and clinical
studies. CpG A is a mix of phosphodiester/phosphorothio-
ate backbone with palindromic sequences and poly G tail,
and is a potent pDC activator and IFNα inducer [65]. CpG
B only has phosphorothioate backbone. CpG B strongly ac-
tivates B cells and promotes pDC and monocyte matur-
ation [66]. CpG C is a hybrid of the two above [67]. CpG
has been used in clinical trials of therapeutic cancer vac-
cines against melanoma, breast/lung/ovarian cancers, sar-
coma and glioblastoma [68–72]. Overall, the vaccines
induced both humoral and cellular responses, but clinical
benefit remained uncommon.
STING agonist
In 2006, TLR-independent antiviral responses (i.e. type 1
interferon induction) were shown to be induced by
double stranded (ds) DNA in the cytosol [73]. Later,
dsDNA was found to activate the transcription factor
NF-kB and IRF3 via an endoplasmic reticulum adaptor
called STING (stimulator of interferon genes) [74]. In
2013, the receptor for cytosolic DNA, the cylic GMP-
AMP synthase or cGAS, was discovered [75]. Upon
binding to cytosolic DNA, cGAS catalyzes the synthesis
of cGAMP which in turns binds to and activates the
adaptor protein STING. Recent results indicate that
spontaneous T cell priming against tumor antigen re-
quires STING-dependent type I IFN induction [76]. Very
promising results from preclinical studies with STING
agonists injected directly into tumors in the aggressive
B16 melanoma model had led to high excitement for
their application in clinical trials [77]. Recent results also
indicate that STING agonists can function as adjuvant
in a setting of whole-cell tumor cell vaccine [78]. It will
be interesting to see how STING agonists compare to
TLR agonists as adjuvants for peptide vaccines in animal
models and clinical trials, and whether their combined




The most notable cytokine which has been extensively
used for immunotherapy is IL-2. IL-2 was initially des-
cribed as a T cell growth factor (TCGF) responsible for
the clonal expansion, differentiation and survival of T cells
[79], and later of activated B cells and natural killer (NK)
cells as well [80, 81]. Although CD4 T cells are the major
source of IL-2 in vivo, CD8 T cells, NK cells and DC can
also produce IL-2 [82–85]. IL-2 was FDA-approved for
the therapy of metastatic renal cell carcinoma in 1992 and
metastatic melanoma in 1998 [86, 87]. IL-2 mediates anti-
tumor activity by activating tumor-specific T cells and NK
cells. In mice, addition of IL-2 to experimental cancer vac-
cines can greatly increase the therapeutic efficacy [10, 48].
IL-15 signals through the same IL-2 Rβγ complex also
used by IL-2, and can also promote peptide-induced T cell
proliferation, especially in T cells with low-affinity TCRs
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[88]. In patients with melanoma, addition of an experi-
mental gp100 peptide/IFA vaccine to IL-2 gave a higher
clinical response rate than observed in patients receiving
IL-2 alone, and also higher than previously observed for
gp100 peptide vaccine alone, suggesting IL-2 can also
function as a vaccine adjuvant in humans [89]. However,
IL-2 can also expand immunosuppressive regulatory T
cells (Treg) which may dampen the immune response or
anti-tumor efficacy [90]. Because Treg express both IL-
2Rα and IL-2Rβγ while CTL express only the latter,
blocking IL-2Rα when using IL-2 preferentially expands
CTL [91]. Recently, a mutant form of IL-2 (IL-2 mutein)
was reported to have higher antitumor efficacy with re-
duced proliferation induction on Treg, possibly thanks to
preferential binding to IL-2Rβγ but not IL-2Rα [92]. Simi-
larly, IL-2 pre-complexed with IL-2-specific antibodies,
and IL-2 covalently modified with polyethylene glycol
have shown selective binding to IL-2Rβγ but not IL-2Rα,
favoring selective effects on CD8+ T cells [93, 94]. If these
modifications also lower the toxicity of IL-2, which may
be partly mediated by IL-2Rα, these IL-2-based com-
pounds may make a comeback in cancer immunotherapy,
including as vaccine adjuvants [91].
Granulocyte-macrophage colony stimulating factor
(GM-CSF)
GM-CSF is a cytokine used as a cancer vaccine adjuvant,
sometimes with success. GM-CSF can be produced by
many cell types including myeloid cells, lymphocytes,
fibroblast, endothelial/epithelial/mesothelial cells and cer-
tain tumor cells [95]. The production of GM-CSF is in-
duced by bacterial toxin and inflammatory cytokines such
as IL-1, IL-6, and TNF-α [96]. GM-CSF receptor is found
on myeloid cells and non-hematopoietic cells such as
endothelial cells. In vaccine settings, GM-CSF has been
shown to initiate the recruitment and maturation of DC
as well as activation of macrophages, neutrophils, and NK
cells, indicating that it is a potential vaccine adjuvant [97,
98]. Combination of GVAX (irradiated tumor cell express-
ing GM-CSF) with anti-CTLA-4 and anti-PD-1 check-
point blockade was very promising in preclinical studies,
leading to the first clinical trials of checkpoint blockade in
patients with cancer. Recombinant GM-CSF has been
used in peptide vaccine trials in mouse and man, where it
has had varying success in raising T cell responses. This
may be partially due to a balance between pro- and anti-
inflammatory properties of GM-CSF depending on its
dose [29]. In addition, there appear to be complex interac-
tions between GM-CSF and other factors in the tumor-
conditioned microenvironment that influence its abil-
ity to either enhance or reduce vaccine-induced T cell
responses [99–102]. Several positive peptide/protein
vaccine trials have incorporated GM-CSF [13, 103];
however due to the lack of a vaccine arm without GM-
CSF, its exact impact on clinical outcome remains un-
known [104, 105].
Interferons (IFNs)
IFNs are of great interest for adjuvant development,
owing to their pleiotropic effect on different immune cells
such as DC, B cells and T cells as well as non-immune
cells. IFN-α and IFN-β promote DC maturation, including
the up-regulation of MHC and costimulatory molecules. In
virus-infected cells, type I IFNs prevent virus replication by
halting transcriptional and translational machineries,
accelerating RNA degradation by inducing RNase L and
inducing apoptosis [106]. IFN-α and pegylated IFN-α
have been approved for advanced renal cell carcinoma
and chronic hepatitis C treatment, respectively, and
both are given after surgical resection of primary mel-
anoma to reduce the chance of recurrence [107]. Pre-
clinical studies showed direct adjuvant efficacy of type I
IFN in a peptide-based anti-melanoma vaccine, where it
promoted T cell numbers, longevity and effector function,
resulting in improved tumor control [108]. In contrast to
type I IFN, IFN-γ (the sole type II IFN) is typically only
produced by specialized immune cells including T cells,
NK cells and NKT cells [109]. Recombinant IFN-γ (or gen-
etically engineered IFN-γ1b) is approved to treat chronic
granulomatous disease [110]. In cancer immunotherapy, a
phase III clinical trial combining chemotherapy with IFN-γ
for patients with advanced ovarian and peritoneal carcino-
mas was terminated due to serious adverse effects [111].
Lessons learned from a few successful peptide-based cancer
vaccine clinical trials
A vaccine comprised of long peptide from HPV-16 viral
oncoproteins E6 and E7 emulsified in IFA was shown to
be very effective in treating vulvar intraepithelial neopla-
sia, a precancerous condition in HPV-16 positive women
[112]. The overall clinical response was 79 % while
complete response was 47 %, after 2 years of follow-up.
This remarkable result with an IFA-based peptide vac-
cine was consistent with our findings that long peptides
did not cause severe sequestration of T cells at the
vaccination site as discussed above. In a phase 3 trial for
patients with advanced melanoma, combination of IL-2
with short gp100 (209–217) peptide emulsified in IFA
resulted in a modest but significant improvement of
overall clinical responses, progression-free survival and
overall survival, compared to IL-2 treatment alone [89].
Based on some of the preclinical results with IFA dis-
cussed above, a less persistent, and therefore less T cell
sequestering, vaccine formulation might result in more
dramatic synergy with IL-2. Indeed, given new insights
into the nature of tumor antigens (short vs. long pep-
tides, as well as mutated vs. non-mutated antigens) and
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adjuvants, there is ample opportunity to design new,
more effective cancer vaccines. A clinical trials in renal
cell cancer with the multiple peptide-based, GM-CSF-
adjuvanted, water-formulated IMA091 vaccine showed
that the breadth of CTL response significantly associated
with clinical benefit, perhaps by limiting antigen-loss
escape mechanisms [104, 113]. Taken together, results
from these clinical studies underscore the importance of
the nature and delivery of target antigens, and the
provision of the right adjuvant.
Cancer vaccines and T cell checkpoint blockade
While blockade of CTLA-4 and PD-1 T cell checkpoints
shows strong activity in a variety of cancers, many patients
do not respond, likely due to insufficient spontaneous
anti-tumor T cell immunity (a lack of tumor reactive T
cells and/or poor T cell infiltration into the tumor).
Vaccination can enhance tumor-specific immunity, and
vaccination is therefore a prime candidate for combination
with checkpoint blockade therapy. Interestingly, the 676-
patient study that led to FDA approval of anti-CTLA-4
revealed that concurrent vaccination with gp100 peptide
vaccine in IFA did not enhance therapeutic efficacy, and
in fact modestly but significantly decreased overall res-
ponse rate and disease control rate through an unknown
mechanism [114]. This has led to uncertainty about
whether and how to combine vaccination with checkpoint
blockade, hampering efforts to improve overall response
rates in melanoma and especially in other, less immuno-
genic cancers. When modeled in mice, we indeed observe
that gp100/IFA vaccination does not synergize with
CTLA-4 or PD-1, and that this effect is due to T cell
entrapment, even of anti-CTLA-4 therapy-induced T
cells, at the gp100/IFA vaccination site. Nevertheless,
by choosing different vaccine formulations, great syn-
ergy between peptide vaccine and checkpoint blockade
can be achieved (unpublished results). Other preclinical
work also indicates synergy between checkpoint blockade
and other classes of non-persistent vaccines, opening the
possibility that vaccines that do not induce excessive T cell
sequestration may combine well with checkpoint blockade
therapy [78, 99].
The need for combining different adjuvants into a single
vaccine
Much preclinical work suggests that combining different
adjuvants is needed to induce a strong anti-tumor immune
response [115]. Accumulated evidence has shown that
CD40 signaling synergizes with almost all TLR ligand indu-
cing far better cellular and humoral responses than that of
each individual adjuvant [116, 117]. Several groups have
shown that almost all TLR agonists synergize with CD40
signaling to enhance CTL expansion and function, in part
by inducing the co-stimulatory molecule CD70 on DC
[118]. We found that adding IL-2 to a TLR7 agonist/CD40
agonist combination further enhanced CD8 T cell peak
effector and memory response, and anti-tumor efficacy
[10]. Second, some adjuvants may possess both desired
and undesired adjuvant properties. By combining with
other adjuvants, the immune response can be skewed to-
ward favorable one, as in the above-mentioned example of
alum combined with MPL which is used in HPV vaccine
and HBV vaccine to promote Th1 response [119]. A major
obstacle to successful translation of these long-known pre-
clinical findings is the observable paucity of clinical trials
where multiple pharmaceutical companies combine their
respective promising, potent agents to create a truly
powerful cancer vaccine. This limitation is slowly begin-
ning to be addressed by the initiation of co-development
agreements between companies, as well as by the develop-
ment of multiple synergistic adjuvants within single com-
panies. Thus, clinical trials of cancer vaccines consisting of
multiple antigens formulated in adjuvants consisting of
short-lived depots with multiple classes of synergistic
immunostimulatory molecules may finally become a
reality.
Adjuvant-free peptide vaccine
There is an emerging new trend of adjuvant-free vaccine
that uses self- assembling peptides. Such peptides were
constructed to have a domain which helps them assemble
into nanofiber structure [120]. Preclinical studies using
mouse model showed self-assembling peptides could elicit
humoral as well as cellular responses [120–122]. The
humoral response was shown to be T cell independent,
possibly due to cross-liking of repetitive epitopes of nano-
fiber peptides to B cell receptors. Yet, mechanisms of how
self-assembling peptides can trigger cellular responses re-
main undefined. Nevertheless, we anticipate that while
self-assembling peptide cancer vaccines can possibly by-
pass the need for a separate antigen delivery system, they
will still needs immunopotentiators to optimally activate T
cells as well as protecting them from tumor suppressive
mechanisms to ultimately maximize therapeutic vaccine
efficacy.
Conclusion
Cancer vaccines are attracting new interest as combin-
ation partners with other immunotherapies, in particular
T cell checkpoint blockade approaches. A detailed un-
derstanding of the mechanism of action of anti-cancer
vaccination is critical for the design of potent vaccine
approaches that induce robust T cell responses. Vaccine
adjuvants are a major, required component of successful
vaccines, and several novel adjuvants are now making
their appearance in the clinic, bridging the wide gap
between preclinical and clinical cancer vaccine formula-
tions. This translational effort is further guided by early
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signs of success in a few clinical trials. The hope is that
these new cancer vaccines, alone or in combination with
CTLA-4 and PD-1 checkpoint blockade, will increase
the duration and quality of life of patients with cancer.
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